Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker

Background: Elevated plasmatic lactate dehydrogenase (LDH) levels are associated with worse prognosis in various malignancies, including metastatic breast cancer (MBC). Nevertheless, no data are available on the prognostic role of LDH as a dynamic biomarker during first-line treatment in unselected...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Pelizzari, Giacomo, Basile, Debora, Zago, Silvia, Lisanti, Camilla, Bartoletti, Michele, Bortot, Lucia, Vitale, Maria Grazia, Fanotto, Valentina, Barban, Serena, Cinausero, Marika, Bonotto, Marta, Gerratana, Lorenzo, Mansutti, Mauro, Curcio, Francesco, Fasola, Gianpiero, Minisini, Alessandro Marco, Puglisi, Fabio
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6770929/
https://ncbi.nlm.nih.gov/pubmed/31450641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11091243
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars